Literature DB >> 29464398

Discussions about predictive genetic testing for Lynch syndrome: the role of health professionals and families in decisions to decline.

Anaita Kanga-Parabia1, Clara Gaff2,3, Louisa Flander4, Mark Jenkins4, Louise A Keogh5.   

Abstract

Unaffected relatives of individuals with Lynch syndrome can be offered predictive genetic testing to guide surveillance recommendations. The decision-making process of those who decline testing, particularly those who do not attend a clinical genetics service, is poorly understood. We have addressed this gap by interviewing 33 individuals from Lynch syndrome mutation-carrying families, unaffected by cancer, who declined predictive genetic testing. Here, we analyse the data provided by 20 participants who unequivocally declined testing. Those who indicated they did not have enough information to make a decision or intended to undergo testing in the future were excluded. Analysis revealed that few decliners discussed their decision with general practitioners or genetic counsellors. Family members were commonly involved to varying degrees, with participants either (1) making group decisions with family members, (2) feeling persuaded by family members to either accept or decline testing, (3) discussing the test but making their own decision. A minority did not discuss testing with family members while making their decision. This research reveals the health communication activities of an understudied group, those declining predictive testing, and indicates that for many, health professionals play a minor role in the decision compared to family.

Entities:  

Keywords:  Communication; Decision making; Decliners; Lynch syndrome; Predictive genetic testing; Qualitative methods

Mesh:

Year:  2018        PMID: 29464398      PMCID: PMC6102092          DOI: 10.1007/s10689-018-0078-2

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  37 in total

1.  Predictive genetic testing and beyond: a theory of engagement.

Authors:  Marion McAllister
Journal:  J Health Psychol       Date:  2002-09

2.  Choosing not to undergo predictive genetic testing for hereditary colorectal cancer syndromes: expanding our understanding of decliners and declining.

Authors:  Louise A Keogh; Heather Niven; Alison Rutstein; Louisa Flander; Clara Gaff; Mark Jenkins
Journal:  J Behav Med       Date:  2017-02-14

3.  Informing one's family about genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): a retrospective exploratory study.

Authors:  Ilse Mesters; Marlein Ausems; Sophie Eichhorn; Hans Vasen
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

4.  Cancer risks for MLH1 and MSH2 mutation carriers.

Authors:  James G Dowty; Aung K Win; Daniel D Buchanan; Noralane M Lindor; Finlay A Macrae; Mark Clendenning; Yoland C Antill; Stephen N Thibodeau; Graham Casey; Steve Gallinger; Loic Le Marchand; Polly A Newcomb; Robert W Haile; Graeme P Young; Paul A James; Graham G Giles; Shanaka R Gunawardena; Barbara A Leggett; Michael Gattas; Alex Boussioutas; Dennis J Ahnen; John A Baron; Susan Parry; Jack Goldblatt; Joanne P Young; John L Hopper; Mark A Jenkins
Journal:  Hum Mutat       Date:  2013-03       Impact factor: 4.878

5.  How do researchers manage genetic results in practice? The experience of the multinational Colon Cancer Family Registry.

Authors:  Louise A Keogh; Douglass Fisher; Sherri Sheinfeld Gorin; Sheri D Schully; Jan T Lowery; Dennis J Ahnen; Judith A Maskiell; Noralane M Lindor; John L Hopper; Terrilea Burnett; Spring Holter; Julie L Arnold; Steven Gallinger; Mercy Laurino; Mary-Jane Esplen; Pamela S Sinicrope
Journal:  J Community Genet       Date:  2013-05-24

Review 6.  Screening participation predictors for people at familial risk of colorectal cancer: a systematic review.

Authors:  Driss Ait Ouakrim; Trevor Lockett; Alex Boussioutas; Louise Keogh; Louisa B Flander; John L Hopper; Mark A Jenkins
Journal:  Am J Prev Med       Date:  2013-05       Impact factor: 5.043

7.  Barriers to participating in genetic counseling and BRCA testing during primary treatment for breast cancer.

Authors:  Kathryn J Schlich-Bakker; Herman F J ten Kroode; Carla C Wárlám-Rodenhuis; Jan van den Bout; Margreet G E M Ausems
Journal:  Genet Med       Date:  2007-11       Impact factor: 8.822

8.  Is uptake of genetic testing for colorectal cancer influenced by knowledge of insurance implications?

Authors:  Louise A Keogh; Christine M van Vliet; David M Studdert; Judith A Maskiell; Finlay A Macrae; D James St John; Clara L Gaff; Mary Anne Young; Melissa C Southey; Graham G Giles; Doreen A Rosenthal; John L Hopper; Mark A Jenkins
Journal:  Med J Aust       Date:  2009-09-07       Impact factor: 7.738

9.  Barriers and motivators for referral of patients with suspected lynch syndrome to cancer genetic services: a qualitative study.

Authors:  Yen Y Tan; Lisa J Fitzgerald
Journal:  J Pers Med       Date:  2014-02-18

10.  Knowledge, attitudes and referral patterns of lynch syndrome: a survey of clinicians in australia.

Authors:  Yen Y Tan; Amanda B Spurdle; Andreas Obermair
Journal:  J Pers Med       Date:  2014-05-12
View more
  4 in total

1.  Study protocol: the Australian genetics and life insurance moratorium-monitoring the effectiveness and response (A-GLIMMER) project.

Authors:  Louise Keogh; Paul Lacaze; Jane Tiller; Aideen McInerney-Leo; Andrea Belcher; Tiffany Boughtwood; Penny Gleeson; Martin Delatycki; Kristine Barlow-Stewart; Ingrid Winship; Margaret Otlowski
Journal:  BMC Med Ethics       Date:  2021-05-21       Impact factor: 2.652

2.  What would I do? Perspectives on the factors underlying Lynch syndrome genetic testing and results sharing decisions for high-risk colorectal cancer patients.

Authors:  Gabriella Tiernan; Victoria Freeman; April Morrow; Emily Hogden; Karen Canfell; Yoon-Jung Kang; Natalie Taylor
Journal:  Psychooncology       Date:  2021-11-08       Impact factor: 3.955

3.  Fertility-sparing treatment for endometrial cancer and atypical endometrial hyperplasia in patients with Lynch Syndrome: Molecular diagnosis after immunohistochemistry of MMR proteins.

Authors:  Ursula Catena; Luigi Della Corte; Antonio Raffone; Antonio Travaglino; Emanuela Lucci Cordisco; Elena Teodorico; Valeria Masciullo; Giuseppe Bifulco; Attilio Di Spiezio Sardo; Giovanni Scambia; Francesco Fanfani
Journal:  Front Med (Lausanne)       Date:  2022-08-25

4.  A novel MLH1 mutation in a Japanese family with Lynch syndrome associated with small bowel cancer.

Authors:  Yoshika Akizawa; Toshiyuki Yamamoto; Kazuo Tamura; Toshiyuki Kanno; Nobuko Takahashi; Takeshi Ohki; Teppei Omori; Katsutoshi Tokushige; Masakazu Yamamoto; Kayoko Saito
Journal:  Hum Genome Var       Date:  2018-06-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.